e.ferrari
TL2 · Turku
Contributes reviews on supplier material. Based in Turku.
Joined 7 May 2025 · last posted 3d
84Posts here
3Topics
1Solutions
162Likes received
153Likes given
18Badges
78Days visited
468Posts read
Recent activity
Full stream-
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still… Replied, post #47 · Compounds › Retatrutide · 25 Jul 2026 · 2 likes Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that…
-
Journal club: what we got wrong in an earlier session Replied, post #113 · Evidence › Journal club · 23 Jul 2026 · 10 likes Post #110 is the version of this I will quote in future. One addition. The baseline characteristics table is the single most useful page for the questions that get…
-
Risk-of-bias tools and the judgement they conceal — does this still hold? Replied, post #28 · Evidence › Meta-analyses · 19 Jul 2026 · 0 likes Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be…
-
Here for the analytics and not much else Replied, post #25 · Lounge › Introductions · 12 Jul 2026 · 1 like Clinician voices are genuinely welcome and are asked to be explicit about the line. Several members here say plainly in every post that they are describing general…
-
[2026 update] Regional warehouse stock versus direct despatch Replied, post #131 · Sourcing › Logistics · 11 Jul 2026 · 3 likes This is the answer, and the reason it is the answer is the more useful part.
-
Micro-titration: a disputed topic, argued properly — one year on Replied, post #61 · Practice › Dosing & titration · 10 Jul 2026 · 1 like Picking up post #59: that is the part I would want checked first. A titration plan written down in advance is easier to stick to and easier to abandon deliberately. An…
-
Insurance and replacement policies, compared Replied, post #75 · Sourcing › Logistics · 9 Jul 2026 · 6 likes Understood. Thank you for being specific about the limits of it.
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Started this topic · Compounds › Tirzepatide · 9 Jul 2026 · 23 likes What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the…
-
Aggregate verification data across the directory, with caveats Replied, post #33 · Sourcing › Independent verification · 7 Jul 2026 · 12 likes I read post #29 twice before replying, because I had assumed the opposite. The arithmetic on aggregate verification data is the easy part and it is where the errors…
-
Pooling trials with different estimands Replied, post #51 · Evidence › Meta-analyses · 26 Jun 2026 · 23 likes I would keep pooling trials with different estimands and the decision it usually gets used for separate in this thread. They are related and they are not the same…
-
Angle of injection and whether 90 degrees is always right — the long version Replied, post #26 · Practice › Administration · 18 Jun 2026 · 0 likes The single most common technique error described here is drawing to the wrong graduation because the barrel was read at an angle. Read it straight on, at eye level,…
-
Reading a trial's population section before its results Replied, post #110 · Evidence › Trials · 10 Jun 2026 · 0 likes Post #107 answers the question as asked. The question underneath it is different. Risk of bias: structured appraisal of internal validity. Key things to assess:…